Worth reading
80Important
Scored from 1 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
51
Hundreds of millions of yenWording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Summary of Q&ASecond quarter (interim period) of the fiscal year ending July 20263 items taken from the company’s own explanation
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- M&A: Negotiations are under way with domestic companies for 2 small and 2 large transactions. Synergies and the probability of growth are key priorities.
- R&D expenses: Initial investment may be required as drug discovery development accelerates, and the company plans to budget funds to increase the probability of success.
- Next medium-term management plan: The company aims to announce the plan during the current fiscal year and will maintain its focus on growing the 6 fields.
- CasMab A and B: The company is basically considering out-licensing after discussing the timing for enhancing their value and the form of the agreements.
- Adrenomedullin: The company is also considering in-house sales, depending on the outcome of discussions with the National Cerebral and Cardiovascular Center.
- Pharmaceutical sales structure: The company plans to establish a structure that supplements its insufficient expertise in clinical trials and marketing authorization.
New initiatives
- M&A negotiations with domestic companies involving 2 small and 2 large transactions
- Accelerating development and increasing R&D investment in drug discovery
- Considering out-licensing CasMab A and B
- Considering in-house sales of adrenomedullin
- Establishing a structure to supplement the expertise required for pharmaceutical clinical trials and marketing authorization
Medium-term management plan targets
The company is preparing to announce its next medium-term management plan during the current fiscal year. Its policy is to designate the food, cosmetics, pharmaceuticals, agriculture, textiles, and battery materials fields as 6 growth areas.| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending July 2026 |
| Medium-term management plan targets | The company is preparing to announce its next medium-term management plan during the current fiscal year. Its policy is to designate the food, cosmetics, pharmaceuticals, agriculture, textiles, and battery materials fields as 6 growth areas. |
| Key points of the Q&A | M&A: Negotiations are under way with domestic companies for 2 small and 2 large transactions. Synergies and the probability of growth are key priorities., R&D expenses: Initial investment may be required as drug discovery development accelerates, and the company plans to budget funds to increase the probability of success., Next medium-term management plan: The company aims to announce the plan during the current fiscal year and will maintain its focus on growing the 6 fields., CasMab A and B: The company is basically considering out-licensing after discussing the timing for enhancing their value and the form of the agreements., Adrenomedullin: The company is also considering in-house sales, depending on the outcome of discussions with the National Cerebral and Cardiovascular Center., Pharmaceutical sales structure: The company plans to establish a structure that supplements its insufficient expertise in clinical trials and marketing authorization. |
| New initiatives | M&A negotiations with domestic companies involving 2 small and 2 large transactions, Accelerating development and increasing R&D investment in drug discovery, Considering out-licensing CasMab A and B, Considering in-house sales of adrenomedullin, Establishing a structure to supplement the expertise required for pharmaceutical clinical trials and marketing authorization |
Items this document does not state (26)
Net SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The eggshell membrane business accelerated as a result of ¥5.1 billion in research funding from NEDO (New Energy and Industrial Technology Development Organization). Going forward, the company plans to budget the funds necessary to increase the probability of success and to grow the food, cosmetics, drug discovery, battery, agriculture, and textile fields in a balanced manner.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.